Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/II study of DB-1324 in advanced/metastatic gastrointestinal tumors
CTR20261089Phase 2Active
- Sponsor
- AbbVie Inc.
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DB-1324 in gastrointestinal neoplasia, sponsored by AbbVie Inc.. Started May 2026; status: active.
02
Drugs
DB-1324
03
Conditions
gastrointestinal neoplasia
Beyond the preview
Go deeper on CTR20261089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261089.